BIOCON News Today

Biocon Ltd Share Price

BIOCON

CMP as on 21-Jun-24 12:00
₹ 346

icon 2.90 | 0.85%

Open
₹ 346
Turnover(lac)
₹ 32,153
Prev. Close
₹ 342.80
Day's Vol (shares)
₹ 9,300,900
Day's Vol (shares)
₹ 340.10         ₹ 351.00

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Image not found

Biocon gets USFDA approval for its micafungin drug

Biocon's consolidated net profit decreased by 57% to ₹136 Crore in the fourth quarter of March 2024 due to increased expenses.

  • 04 Jun, 2024 |
  • 12:59 PM
Image not found

Handok to market Biocon's weight loss drug in South Korea

One of the top companies in South Korea for diabetes management is Handok, which provides a range of services from diagnosis to care and treatment.

  • 24 May, 2024 |
  • 12:59 PM
Image not found

Biocon's biosimilar drug for eye treatment gets USFDA approval

This approval builds on company’s successful track record of bringing the first interchangeable insulin, Semglee.

  • 22 May, 2024 |
  • 12:04 PM
Image not found

Medix to distribute Biocon's obesity drug in Mexico

The partnership follows Biocon's success in becoming the first business to receive approval for gLiraglutide in an ICH country.

  • 14 May, 2024 |
  • 11:21 AM
Image not found

Biocon joins hands with Biomm to commercialize diabetes drug in Brazil

Biomm's Nova Lima production facility is dedicated to the development, manufacture, and commercialization of complex biotech and biosimilar medicinal products.

  • 18 Apr, 2024 |
  • 11:06 AM
Image not found

Biocon's Liraglutide Approval Spurs Stock Rise, Eyes UK Market Expansion

The application for Liraglutide was filed by Biocon through its European partner, Zentiva.

  • 28 Mar, 2024 |
  • 3:02 PM
Image not found

Biocon Biologics slips ~6% after CFO Indranil Sen steps down

Indranil Sen has resigned to seek possibilities outside of the organisation.

  • 15 Mar, 2024 |
  • 2:28 PM
Image not found

Eris Lifesciences purchases Biocon Biologics’ domestic brand formulations biz

As part of the agreement, around 430 people from the company are scheduled to migrate to Eris.

  • 15 Mar, 2024 |
  • 11:38 AM
Image not found

Biocon soars on US market entry deal with J&J

Under the terms of the agreement, the product may be introduced in the US in February 2025 after receiving FDA approval.

  • 01 Mar, 2024 |
  • 11:31 AM
Image not found

Biocon Faces ₹3 Crore Penalty Over GST-Related Issues, Plans Appeal

The penalty of ₹3,03,78,465 was imposed on February 22, 2024, by the Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalor

  • 26 Feb, 2024 |
  • 4:20 PM